Ublituximab, an Optimized Anti-CD20 Monoclonal Antibody, Demonstrates Greater NK-Mediated ADCC Than Rituximab in Waldenstrom’s Macroglobulinemia Patients Supporting a Therapeutic Strategy with Ublituximab.

Drug Category: Array
Conference Category: Array
Lead Author: Le Garff-Tavernier M, Leblond V, et al.
Published Date: 11/12/2012
Download Link: /wp-content/uploads/2019/03/ASH2012Poster1654.pdf
Download Text: Download
Popup Confirmation?:
site-sidebar-layout: default
ast-site-content-layout: default
site-content-style: default
site-sidebar-style: default
theme-transparent-header-meta: default
stick-header-meta: default
astra-migrate-meta-layouts: set
Scroll to Top